我要投票 中生方政NBF在医疗器械行业中的票数:1022
· 外 推 电 报 ·
2025-11-23 01:48:05 星期日

【中生方政NBF是哪个国家的品牌?】

中生方政NBF是什么牌子?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生方政NBF品牌出海!将品牌入驻外推网,定制中生方政NBF品牌推广信息,可以显著提高中生方政NBF产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


英文翻译:Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://www.waitui.com/brand/2c7dece2d.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

《大型网络平台个人信息保护规定(征求意见稿)》公开征求意见

36氪获悉,国家互联网信息办公室、公安部就《大型网络平台个人信息保护规定(征求意见稿)》公开征求意见。征求意见稿提出,大型网络平台服务提供者应当将在中华人民共和国境内运营中收集和产生的个人信息存储在境内。确需向境外提供的,应当符合国家数据出境安全管理有关规定。大型网络平台服务提供者应当按照国家有关规定,健全个人信息出境安全相关技术和管理措施,及时防范、处置个人信息违法违规出境安全风险和威胁。

2小时前

宁德时代与上汽商用车达成深度战略合作

36氪获悉,11月22日,据宁德时代微信公众号,在第21届广州国际车展上,宁德时代与上汽商用车正式宣布达成深度战略合作。双方将围绕“技术共研、生态共建、全球共进”三大方向,在商用车新能源化、智能化领域全面深化合作,共同构建“车、电、站、云”一体化的智慧换电生态与绿色运力体系。

2小时前

北京“十四五”期间企业直接融资超5.6万亿元

据新华社,记者从日前举行的首都“十四五”规划高质量收官系列主题新闻发布会金融业发展成就专场上获悉,“十四五”期间,北京地区多元化融资渠道进一步拓宽,企业实现直接融资超5.6万亿元。金融“五篇大文章”合计贷款余额6.8万亿元,高于人民币各项贷款增速2.1个百分点,为首都经济持续向好和高质量发展营造良好的金融环境。(新华网)

2小时前

李斌:乐道也将有右舵车型

36氪获悉,11月21日,蔚来创始人李斌表示:乐道接下来也会有右舵车型,它需要时间。 今年11月18日,蔚来旗下高端小车品牌萤火虫的右舵车型正式量产,首批将发运至新加坡市场。未来,乐道也将推出右舵车型。

2小时前

鸭绒价格近期仍在高位 中下游追单采购意愿活跃

财联社记者从业内了解到,羽绒服目前进入消费旺季,“(白鸭绒价)10月份几乎是一天一个价,这段时间没有在涨,维持在高位。”尽管多数企业认为当前的原料价格偏高,但由于前期备货不足,促使中下游的追单采购意愿保持活跃。上市公司方面,记者采访获悉华英农业羽绒加工产能满产;古麒绒材当前整体羽绒产能2288吨,公司具备一定数量的鸭绒和鹅绒库存,随着羽绒价格上涨,公司库存相应增值。(财联社)

2小时前

本页详细列出关于中生方政NBF的品牌信息,含品牌所属公司介绍,中生方政NBF所处行业的品牌地位及优势。
咨询